433 research outputs found
Π‘Π΅ΠΏΡΠΈΡ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΡΠ½ΡΠ΅ΡΠ°Π»ΠΎΠΏΠ°ΡΠΈΡ (ΠΎΠ±Π·ΠΎΡ)
International studies demonstrate an annual increase in the frequency and impact of sepsis in intensive care units (ICU). Cerebral dysfunction, or so-called sepsis-associated encephalopathy (SAE), is one of the earliest signs of sepsis, as well as its common complication. Up to 70% of patients with sepsis have symptoms of encephalopathy [1, 2]. A direct link between the SAE and an increased mortality rate is a major concern; more than a half of sepsis survivors experience continuous memory and concentration impairment [3β5]. Diagnosis of the cerebral dysfunction in sepsis is often difficult because of lack of specific biomarkers and frequent prescription of sedatives to critically ill patients. Clinical manifestations of SAE are diverse, may vary from simple malaise and lack of concentration to deep coma. The literature discusses probable mechanisms of formation and development of septic encephalopathy, such as oxidative stress, inflammation, mitochondrial and endothelial dysfunction, increased permeability of the blood-brain barrier, impairment of macro- and microcirculation, changes in neirotransmission, activation of microglia. The lack of clear data and consensus about the etiology and mechanisms of SAE at present does not permit predicting its development and prescribing a specific therapy. The review discusses current understanding of the causes of septic encephalopathy, methods of diagnosis, the main clinical manifestations, key mediators, and pathophysiological mechanisms. A hypothesis is proposed that poses a contribution of aromatic microbial metabolites (AMM) of phenol and indole nature (products of bacterial biodegradation of tyrosine and tryptophan) to the development of brain dysfunction. The fields of exploratory studies, which might open perspectives in the diagnosis, as well as new approaches in the treatment of SAE are outlined.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠΊΠ°Π·ΡΠ²Π°ΡΡ Π½Π° Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΡΠΉ ΡΠΎΡΡ ΡΠ°ΡΡΠΎΡΡ ΠΈ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΠΈ ΡΠ΅ΠΏΡΠΈΡΠ° Π² ΡΠ΅Π°Π½ΠΈΠΌΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΡΡ
. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°Π½Π½ΠΈΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ°ΡΡΡΠΌ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠ΅ΠΌ ΡΠ΅ΠΏΡΠΈΡΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΡ ΠΌΠΎΠ·Π³Π° ΠΈΠ»ΠΈ ΡΠ°ΠΊ Π½Π°Π·ΡΠ²Π°Π΅ΠΌΠ°Ρ ΡΠ΅ΠΏΡΠΈΡ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΡΠ½ΡΠ΅ΡΠ°Π»ΠΎΠΏΠ°ΡΠΈΡ (SAE). ΠΠΎ 70% Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠ΅ΠΏΡΠΈΡΠΎΠΌ ΠΈΠΌΠ΅ΡΡ ΡΠΈΠΌΠΏΡΠΎΠΌΡ ΡΠ½ΡΠ΅ΡΠ°Π»ΠΎΠΏΠ°ΡΠΈΠΈ [1, 2]. ΠΡΠΎΠ±ΠΎΠ΅ Π±Π΅ΡΠΏΠΎΠΊΠΎΠΉΡΡΠ²ΠΎ Π²ΡΠ·ΡΠ²Π°Π΅Ρ ΡΠ°ΠΊΡ ΠΏΡΡΠΌΠΎΠΉ ΡΠ²ΡΠ·ΠΈ SAE Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠΉ Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡΡ, Π° ΡΡΠ΅Π΄ΠΈ Π²ΡΠΆΠΈΠ²ΡΠΈΡ
ΠΏΠΎΡΠ»Π΅ ΡΠ΅ΠΏΡΠΈΡΠ° Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»ΠΎΠ²ΠΈΠ½Ρ ΠΈΠΌΠ΅ΡΡ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠ΅ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π°, Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΏΠ°ΠΌΡΡΠΈ ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π²Π½ΠΈΠΌΠ°Π½ΠΈΡ [3β5]. ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΠΌΠΎΠ·Π³Π° ΠΏΡΠΈ ΡΠ΅ΠΏΡΠΈΡΠ΅ ΡΠ°ΡΡΠΎ Π·Π°ΡΡΡΠ΄Π½Π΅Π½Π° ΠΈΠ·-Π·Π° ΠΎΡΡΡΡΡΡΠ²ΠΈΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ Π² ΡΠ²ΡΠ·ΠΈ Ρ ΡΠ°ΡΡΡΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΡΠ΅Π΄Π°ΡΠΈΠ²Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Ρ ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ SAE ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·Π½Ρ, ΠΌΠΎΠ³ΡΡ Π²Π°ΡΡΠΈΡΠΎΠ²Π°ΡΡ ΠΎΡ ΠΏΡΠΎΡΡΠΎΠ³ΠΎ Π½Π΅Π΄ΠΎΠΌΠΎΠ³Π°Π½ΠΈΡ ΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠ° ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π²Π½ΠΈΠΌΠ°Π½ΠΈΡ Π΄ΠΎ Π³Π»ΡΠ±ΠΎΠΊΠΎΠΉ ΠΊΠΎΠΌΡ. Π Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΠΎΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°Π΅ΠΌΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ΅ΠΏΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ½ΡΠ΅ΡΠ°Π»ΠΎΠΏΠ°ΡΠΈΠΈ, ΡΠ°ΠΊΠΈΠ΅ ΠΊΠ°ΠΊ ΠΎΠΊΠΈΡΠ»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΡΡΠ΅ΡΡ, Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅, ΠΌΠΈΡΠΎΡ
ΠΎΠ½Π΄ΡΠΈΠ°Π»ΡΠ½Π°Ρ ΠΈ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½Π°Ρ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΡ, ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ½ΠΈΡΠ°Π΅ΠΌΠΎΡΡΠΈ Π³Π΅ΠΌΠ°ΡΠΎΡΠ½ΡΠ΅ΡΠ°Π»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π±Π°ΡΡΠ΅ΡΠ°, Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΌΠ°ΠΊΡΠΎ- ΠΈ ΠΌΠΈΠΊΡΠΎΡΠΈΡΠΊΡΠ»ΡΡΠΈΠΈ, ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π½Π΅ΠΉΡΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠΈ, Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΠΌΠΈΠΊΡΠΎΠ³Π»ΠΈΠΈ. ΠΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΠ΅ΡΠΊΠΈΡ
Π΄Π°Π½Π½ΡΡ
ΠΈ Π΅Π΄ΠΈΠ½ΠΎΠ³ΠΎ ΠΌΠ½Π΅Π½ΠΈΡ ΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠΆΠ΄Π΅Π½ΠΈΠΈ ΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ°Ρ
SAE Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°ΡΡ Π΅Π΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ. Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΎΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ ΠΏΡΠΈΡΠΈΠ½Π°Ρ
ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ΅ΠΏΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ½ΡΠ΅ΡΠ°Π»ΠΎΠΏΠ°ΡΠΈΠΈ, ΠΌΠ΅ΡΠΎΠ΄Π°Ρ
Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ, ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ, ΠΊΠ»ΡΡΠ΅Π²ΡΠ΅ ΠΌΠ΅Π΄ΠΈΠ°ΡΠΎΡΡ, ΠΏΠ°ΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ. ΠΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π° Π³ΠΈΠΏΠΎΡΠ΅Π·Π° ΠΎ ΡΠΎΠ»ΠΈ Π°ΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠΈΠΊΡΠΎΠ±Π½ΡΡ
ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠΎΠ² (ΠΠΠ) ΡΠ΅Π½ΠΎΠ»ΡΠ½ΠΎΠΉ ΠΈ ΠΈΠ½Π΄ΠΎΠ»ΡΠ½ΠΎΠΉ ΠΏΡΠΈΡΠΎΠ΄Ρ β ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠ΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ ΡΠΈΡΠΎΠ·ΠΈΠ½Π° ΠΈ ΡΡΠΈΠΏΡΠΎΡΠ°Π½Π° β Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΠΌΠΎΠ·Π³Π°, Π½Π°ΠΌΠ΅ΡΠ΅Π½Ρ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΏΠΎΠΈΡΠΊΠΎΠ²ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΎΡΠΊΡΡΠ²Π°ΡΡΠΈΠ΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ Π½ΠΎΠ²ΡΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ SAE
ΠΡΠΈΠΎΡΡΠΎΠΏΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ COVID-19: ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ
The COVID-19 outbreak started in December 2019 in China has spread over all countries of the world within few month acquiring a pandemic nature, the incident population counting millions. The pathogenic mechanisms of the new coronaviral infection caused by never-before-seen virus SARS-CoV2 are yet to be studied. Various drugs are used for COVID-19 treatment and guidelines are continuously revised as new experience is acquired. In the current pandemic situation, it is important to provide specialists with latest information concerning efficacy and safety drugs for COVID-19 patients and promising research in this field.The purpose of the review is to critically analyze published data on outcomes of COVID-19 treatment with various drugs including potentially promising drugs.The search has been carried out through such databases as PubMed, Scopus, Cyberleninka, https://www.globalclinicaltrialsdata.com, https://clinicaltrials.gov, Cochrane Library; mostly, randomized clinical trials-2020 and papers dedicated to candidate drugs have been considered. The paper is structured based on the drugβs action mechanism and contains parts dedicated to antiviral, immunomodulatory, and antibacterial therapies. Looking for a new promising target in COVID-19 treatment, the authors focus their attention on matrix metalloproteinases (MMP), which abundance results in the destruction of extracellular matrix, epithelial and endothelial basal membranes and leads to secondary lung tissue injury. The paper provides a theoretic justification of MMP inhibitor use by an example of doxycycline and offers an efficacy study protocol for the new approach to COVID-19 therapy.Conclusion: as of now, there are no drugs which efficacy for COVID 19 has been proven. Drugs possessing multiple mechanisms of action are employed beside their specified indications, often in combinations; in this situation, additive side effects with adverse consequences for the patient can hardly be avoided. Administration of drugs with unproven efficacy may be justified only in clinical trials followed by subsequent analysis and publication of findings demonstrating that in case of success, recommendations for a majority of COVID-19 patients could be confidently issued.ΠΠΏΠΈΠ΄Π΅ΠΌΠΈΡ COVID-19, Π½Π°ΡΠ°Π²ΡΠ°ΡΡΡ Π² Π΄Π΅ΠΊΠ°Π±ΡΠ΅ 2019 Π³ΠΎΠ΄Π° Π² ΠΠΈΡΠ°Π΅, Π·Π° Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΌΠ΅ΡΡΡΠ΅Π² ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½ΠΈΠ»Π°ΡΡ Π½Π° Π²ΡΠ΅ ΡΡΡΠ°Π½Ρ ΠΌΠΈΡΠ°, ΠΏΡΠΈΠ½ΡΠ² Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ, ΡΠΈΡΠ»ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²ΡΠΈΡ
ΠΈΡΡΠΈΡΠ»ΡΠ΅ΡΡΡ ΠΌΠΈΠ»Π»ΠΈΠΎΠ½Π°ΠΌΠΈ. ΠΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ, Π²ΡΠ·Π²Π°Π½Π½ΠΎΠΉ Π½Π΅ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠΌ ΡΠ°Π½Π΅Π΅ Π²ΠΈΡΡΡΠΎΠΌ SARS-CoV2, ΠΎΡΡΠ°ΡΡΡΡ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΈΠ·ΡΡΠ΅Π½Π½ΡΠΌΠΈ. ΠΠ»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ COVID-19 ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΡΠ°Π·Π½ΡΡ
Π³ΡΡΠΏΠΏ, ΠΏΠΎ ΠΌΠ΅ΡΠ΅ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΎΠΏΡΡΠ° ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎ ΠΏΠ΅ΡΠ΅ΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ. Π ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠ΅ΠΊΡΡΠ΅ΠΉ ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ Π²Π°ΠΆΠ½ΠΎ ΠΏΡΠ΅Π΄ΠΎΡΡΠ°Π²ΠΈΡΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΡΡΠ°ΠΌ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΡ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎΠ± ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π±Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΡ
Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ COVID-19, ΠΈ ΠΎ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
Π² ΡΡΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ.Β Π¦Π΅Π»Ρ ΠΎΠ±Π·ΠΎΡΠ° β ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ COVID-19 Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΡΡΠΏΠΏ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π΄Π»Ρ Π²ΡΠ±ΠΎΡΠ° Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ².ΠΠΎΠΈΡΠΊ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΏΡΠΎΠ²Π΅Π»ΠΈ ΠΏΠΎ Π±Π°Π·Π°ΠΌ Π΄Π°Π½Π½ΡΡ
PubMed, Scopus, Cyberleninka, Clinical Trials, Cochrane Library ΠΈ Π΄Ρ., ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π»ΠΈ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ 2020 Π³ΠΎΠ΄Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ°Π±ΠΎΡΡ ΠΏΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ²-ΠΏΡΠ΅ΡΠ΅Π½Π΄Π΅Π½ΡΠΎΠ². ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΡΡΠ°ΡΡΠΈ ΡΡΡΡΠΊΡΡΡΠΈΡΠΎΠ²Π°Π½ ΠΏΠΎ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΡΠΎΠ΄Π΅ΡΠΆΠΈΡ ΡΠ°Π·Π΄Π΅Π»Ρ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ, ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠ΅ΠΉ, Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π ΠΏΠΎΠΈΡΠΊΠ΅ Π½ΠΎΠ²ΠΎΠΉ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΌΠΈΡΠ΅Π½ΠΈ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ COVID-19 ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π½Π° ΠΌΠ°ΡΡΠΈΠΊΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π°Π·Π°Ρ
(ΠΠΠ ), ΠΈΠ·Π±ΡΡΠΎΠΊ ΠΊΠΎΡΠΎΡΡΡ
Π²Π΅Π΄Π΅Ρ ΠΊ ΡΠ°Π·ΡΡΡΠ΅Π½ΠΈΡ Π²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ°, Π±Π°Π·Π°Π»ΡΠ½ΡΡ
ΠΌΠ΅ΠΌΠ±ΡΠ°Π½ ΡΠΏΠΈΡΠ΅Π»ΠΈΡ ΠΈ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΡ, ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ Π²ΡΠΎΡΠΈΡΠ½ΠΎΠΌΡ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ. Π ΡΠ°Π±ΠΎΡΠ΅ ΡΠ΅ΠΎΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈ ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π»ΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² MMP Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ Π΄ΠΎΠΊΡΠΈΡΠΈΠΊΠ»ΠΈΠ½Π°, ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠΈΠ»ΠΈ ΠΏΡΠΎΡΠΎΠΊΠΎΠ» ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ COVID-19.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ² Ρ Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ COVID 19 Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π΅Ρ. ΠΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Ρ ΡΠ°Π·Π½ΡΠΌΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ°ΠΌΠΈ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡΡΡ Π½Π΅ ΠΏΠΎ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡΠΌ, ΡΠ°ΡΡΠΎ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡΡ
, Π² ΡΡΠΈΡ
ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΡΡΠ΄Π½ΠΎ ΠΈΠ·Π±Π΅ΠΆΠ°ΡΡ ΡΡΠΌΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΡΡΠ΅ΠΊΡΠΎΠ² Ρ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΠ²ΠΈΡΠΌΠΈ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Ρ Π½Π΅Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΎΠΏΡΠ°Π²Π΄Π°Π½ΠΎ Π»ΠΈΡΡ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ Π°Π½Π°Π»ΠΈΠ·ΠΎΠΌ ΠΈ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠ΅ΠΉ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ², ΡΡΠΎΠ±Ρ Π² ΡΠ»ΡΡΠ°Π΅ ΡΡΠΏΠ΅Ρ
Π° Ρ ΡΠ²Π΅ΡΠ΅Π½Π½ΠΎΡΡΡΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°ΡΡ ΠΈΡ
Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ COVID-19. ΠΠ»ΡΡΠ΅Π²ΡΠ΅ ΡΠ»ΠΎΠ²Π°: COVID-19; ΠΏΡΠΎΡΠΈΠ²ΠΎΠΌΠ°Π»ΡΡΠΈΠΉΠ½ΡΠ΅ ΡΡΠ΅Π΄ΡΡΠ²Π°; ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ Π²ΠΈΡΡΡΠ½ΡΡ
ΠΏΡΠΎΡΠ΅Π°Π·; ΠΏΡΠΎΡΠΈΠ²ΠΎΠΏΠ°ΡΠ°Π·ΠΈΡΠ°ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ; ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½ΠΎΠ²; ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΡΠ½ΡΡ-ΠΊΠΈΠ½Π°Π·; ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Ρ; ΠΏΠ»Π°Π·ΠΌΠ° ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠΎΠ²; ΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄Ρ; ΠΏΡΠΎΠΊΠ°Π»ΡΡΠΈΡΠΎΠ½ΠΈΠ½; Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠΈ; Π½ΠΎΠ²Π°Ρ ΠΌΠΈΡΠ΅Π½Ρ; ΠΌΠ°ΡΡΠΈΠΊΡΠ½ΡΠ΅ ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π°Π·Ρ, Π΄ΠΎΠΊΡΠΈΡΠΈΠΊΠ»ΠΈΠ½
The role of human and microbial metabolites of triptophane in severe diseases and critical ill (review)
The growing interest to metabolites circulating in the blood is associated with the accumulation of factual material on the involvement of low-molecular compounds in the development of a number of serious diseases. This review reveals the effect of a whole class of chemical compounds tryptophan metabolites on various pathological processes. The following keywords were used to find the publications in the PubMed database for the last 10 years: names of natural indole compounds, methods for their detection, nosology of diseases and critical illness . The data are presented in sections, with the studies of tryptophan metabolites in a variety of disease groups, such as cancer, cardiovascular disease, kidney disease, bowel, mental disorders, atherosclerosis, etc. A particular attention is paid to the role of indole compounds that enter the systemic circulation as a result of microbial biotransformation of tryptophan, serotonin and other indole metabolites, which can be attributed to the common metabolites of humans and microbiota. The most interesting clinical studies are summarized in the tables and figures. A number of indole metabolites are considered as potential biomarkers. The authors of the review substantiate the metabolomic approach to the study of a number of oncological, septic, mental and other intractable diseases, which opens up new possibilities of influence on the pathological process by targeted regulation in the metabolome/microbiome system
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ Π±Π΅Π»ΠΊΠ° S100B ΠΏΡΠΈ ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΡΡ
The review deals with possibilities for the quantitative assessment of the degree of brain injury, by measuring the level of S100B protein in various biological fluids. Data are given on changes in the concentration of this protein in different categories of patients, including those who are critically ill. Key words: S100B protein, laboratory diagnosis of critical conditions, biomarkers, perinatal brain lesions.ΠΠ±Π·ΠΎΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ ΠΌΠΎΠ·Π³Π° ΠΏΡΡΠ΅ΠΌ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΠΎΠ²Π½Ρ Π±Π΅Π»ΠΊΠ° S100B Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΆΠΈΠ΄ΠΊΠΎΡΡΡΡ
. ΠΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΠΈΠ½Π° Ρ ΡΠ°Π·Π½ΡΡ
ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΉ Π±ΠΎΠ»ΡΠ½ΡΡ
, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ β Π½Π°Ρ
ΠΎΠ΄ΡΡΠΈΡ
ΡΡ Π² ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠΎΡΡΠΎΡΠ½ΠΈΠΈ. ΠΠ»ΡΡΠ΅Π²ΡΠ΅ ΡΠ»ΠΎΠ²Π°: S100B, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½Π°Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΡΠΎΡΠ½ΠΈΠΉ, Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΡ, ΠΏΠ΅ΡΠΈΠ½Π°ΡΠ°Π»ΡΠ½ΡΠ΅ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°
- β¦